Former TTY Biopharm Co (台灣東洋藥品) chairman Lin Rong-jin (林榮錦) yesterday was sentenced to 10 years in prison on charges of embezzlement — a verdict that he said he would appeal.
A year after Lin’s departure in 2014, TTY Biopharm chairman Clark Hsiao (蕭英鈞) launched a lawsuit against his predecessor alleging that he had caused the company NT$3 billion (US$99.48 million at the current exchange rate) in losses.
The Taipei District Court yesterday found Lin guilty on four counts of violations of the Securities and Exchange Act (證交法), including breach of trust and conducting abnormal transactions.
Photo: Chen Yung-chi, Taipei Times
He also has to turn in 22.89 million euros (US$27.39 million) in unlawful gains, the verdict read.
Lin was accused of in 2013 transferring a number of patents held by TTY Biopharm to Switzerland-based Inopha AG — a company that Lin controls through Center Laboratories Inc (晟德大藥廠), of which he is the chairman — along with all the rights to further develop the intellectual property.
The patents include treatments for breast and ovarian cancers, as well as fungal infections and schizophrenia, which were transferred for Lin’s personal gain at the expense of TTY BioPharm, the ruling said.
Lin said the investigation does not reflect the entirety of the case and that the accusations originated from a personal row with Hsiao, his longtime business partner.
He said that his reputation and track record in Taiwan’s biotechnology sector speaks for itself and that he trusts that the court would uncover the truth.
Lin, a notable figure in the industry who has had a hand in the founding of several Taiwanese biotechnology firms, was enlisted to restructure then-ailing TTY Biopharm in 1994.
Lin helped bring the company back into the black.
He is credited with transitioning a company focused on manufacturing and selling generic drugs to developing and marketing branded and more advanced generic drugs.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained